Amgen (CHIX:AMGD) Gross Profit: €21,829 Mil (TTM As of Mar. 2026)


CHIX:AMGD Amgen Inc CHIX:AMGD
90 GF Score
Price €285.00
GF Value €325.97
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Amgen Gross Profit?

Amgen CHIX:AMGD 90 Gross Profit is €21,829 Mil as of Mar. 2026. GuruFocus rates CHIX:AMGD with a GF Score™ of 90/100 and a GF Value™ of €325.97 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Amgen's gross profit for the three months ended in Mar. 2026 was €5,081 Mil. Amgen's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was €21,829 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Amgen's gross profit for the three months ended in Mar. 2026 was €5,081 Mil. Amgen's Revenue for the three months ended in Mar. 2026 was €7,455 Mil. Therefore, Amgen's Gross Margin % for the quarter that ended in Mar. 2026 was 68.16%.

Amgen had a gross margin of 68.16% for the quarter that ended in Mar. 2026 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Amgen was 82.73%. The lowest was 61.53%. And the median was 75.72%.

Warning Sign:

Amgen Inc gross margin has been in long-term decline. The average rate of decline per year is -3.6%.


Amgen  (CHIX:AMGd) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Amgen had a gross margin of 68.16% for the quarter that ended in Mar. 2026 => Durable competitive advantage


Amgen Gross Profit Related Terms


Amgen Gross Profit Historical Data

* Premium members only.

The historical data trend for Amgen's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Gross Profit Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17,279.63 18,801.65 18,100.66 19,640.53 21,105.76

Amgen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,792.43 5,347.66 5,516.70 5,884.06 5,081.01

CHIX:AMGD vs GILD, PFE, BMY: Gross Profit Comparison

For the Drug Manufacturers - General subindustry, Amgen's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen Gross Profit vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Gross Profit distribution charts can be found below:

* The bar in red indicates where Amgen's Gross Profit falls into.


CHIX:AMGD
90GF Score
Amgen Inc CHIX:AMGD
Gross Profit is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Amgen's Gross Profit for the fiscal year that ended in Dec. 2025 is calculated as

Gross Profit (A: Dec. 2025 )=Revenue - Cost of Goods Sold
=31385.354 - 10279.598
=21,106

Amgen's Gross Profit for the quarter that ended in Mar. 2026 is calculated as

Gross Profit (Q: Mar. 2026 )=Revenue - Cost of Goods Sold
=7454.57 - 2373.56
=5,081

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €21,829 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Amgen's Gross Margin % for the quarter that ended in Mar. 2026 is calculated as

Gross Margin % (Q: Mar. 2026 )=Gross Profit (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=(Revenue - Cost of Goods Sold) / Revenue
=5,081 / 7454.57
=68.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Frequently Asked Questions Learn more about Gross Profit →
What does a Gross Profit of €21,829 Mil mean?
Amgen (CHIX:AMGD) has a Gross Profit of €21,829 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Amgen and its competitors.
Is Amgen's Gross Profit too high?
Amgen's current Gross Profit is €21,829 Mil. Overall, Amgen has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Gross Profit compare to GILD and PFE?
Amgen's Gross Profit of €21,829 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Amgen and its competitors. Amgen's current Gross Profit is €21,829 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (CHIX:AMGD) is currently considered Modestly Undervalued. The stock's GF Value™ is €325.97, compared to a current price of €285.00 — trading 12.6% below its estimated fair value. The current Gross Profit is €21,829 Mil. Amgen's overall GF Score™ is 90/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current Gross Profit is €21,829 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (CHIX:AMGD) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be undervalued. The current stock price of €285.00 is trading 12.6% below its estimated GF Value™ of €325.97. GuruFocus considers Amgen to be Modestly Undervalued.

Key valuation signals for CHIX:AMGD:

  • Gross Profit: €21,829 Mil
  • GF Value™: €325.97 vs. price of €285.00 (12.6% below fair value)
  • GF Score™: 90/100 with 8 warning signs

No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
90GF Score

Get the complete analysis for CHIX:AMGD

Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€285.00
Price
€325.97
GF Value